Strongbridge Biopharma (Strongbridge Biopharma) Market Cap : $135.66 Mil (As of May. 13, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Strongbridge Biopharma Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Strongbridge Biopharma's share price for the quarter that ended in Jun. 2021 was $2.97. Strongbridge Biopharma's Shares Outstanding (EOP) for the quarter that ended in Jun. 2021 was 67.72 Mil. Therefore, Strongbridge Biopharma's market cap for the quarter that ended in Jun. 2021 was $201.14 Mil.

Strongbridge Biopharma's quarterly market cap increased from Dec. 2020 ($163.40 Mil) to Mar. 2021 ($186.43 Mil) and increased from Mar. 2021 ($186.43 Mil) to Jun. 2021 ($201.14 Mil).

Strongbridge Biopharma's annual market cap declined from Dec. 2018 ($242.47 Mil) to Dec. 2019 ($113.29 Mil) but then increased from Dec. 2019 ($113.29 Mil) to Dec. 2020 ($163.40 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Strongbridge Biopharma's Enterprise Value for Today is $90.03 Mil.

Strongbridge Biopharma Market Cap Historical Data

The historical data trend for Strongbridge Biopharma's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strongbridge Biopharma Market Cap Chart

Strongbridge Biopharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Market Cap

Get a 7-Day Free Trial

84.80

291.09

242.47

113.29

163.40

Strongbridge Biopharma Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Market Cap	Get a 7-Day Free Trial															205.47	140.48	163.40	186.43	201.14

Competitive Comparison of Strongbridge Biopharma's Market Cap

For the Biotechnology subindustry, Strongbridge Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strongbridge Biopharma's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Strongbridge Biopharma's Market Cap distribution charts can be found below:

* The bar in red indicates where Strongbridge Biopharma's Market Cap falls into.

Strongbridge Biopharma Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Strongbridge Biopharma's Market Cap for the fiscal year that ended in Dec. 2020 is calculated as

Market Cap (A: Dec. 2020 )	=	Share Price (A: Dec. 2020 )	*	Shares Outstanding (EOP) (A: Dec. 2020 )
	=	$2.43	*	67.2438
	=	$163.40

Strongbridge Biopharma's Market Cap for the quarter that ended in Jun. 2021 is calculated as

Market Cap (Q: Jun. 2021 )	=	Share Price (Q: Jun. 2021 )	*	Shares Outstanding (EOP) (Q: Jun. 2021 )
	=	$2.97	*	67.7223
	=	$201.14

Strongbridge Biopharma (NAS:SBBP) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Strongbridge Biopharma Market Cap Related Terms

Thank you for viewing the detailed overview of Strongbridge Biopharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Strongbridge Biopharma (Strongbridge Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Strongbridge Biopharma PLC (NAS:SBBP) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053

Website

http://www.strongbridgebio.com

Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.

Executives

David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Cdk Associates, L.l.c.	10 percent owner	C/O CAXTON CORPORATION, 731 ALEXANDER ROAD, BUILDING #2, PRINCETON NJ 08540
Bruce Kovner	10 percent owner	C/O CAXTON ASSOCIATES, 500 PARK AVENUE, NEW YORK NY 10022
Caxton Corp	10 percent owner	731 ALEXANDER ROAD, BUILDING 2, SUITE 500, PRINCETON NJ 08540
John Johnson	director, officer: Chief Executive Officer	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Marten Steen	director	60 LEVERONI COURT, NOVATO CA 94949
Hilde H Steineger	director	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Stephen J Long	officer: Chief Legal Officer	C R BARD INC 730 CENTRAL AVENUE MURRAY HILL NJ 07974
Fredric J. Cohen	officer: Chief Medical Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Scott L. Wilhoit	officer: Chief Commercial Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Robert Matthew Lutz	officer: Chief Financial Officer	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Richard S Kollender	officer: Chief Operating Officer	C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
A Brian Davis	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380